Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526. https://doi.org/10.1056/NEJMoa1104621

Article  PubMed  CAS  Google Scholar 

Garon EB et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824

Article  PubMed  Google Scholar 

Postow MA et al (2015) Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017. https://doi.org/10.1056/NEJMoa1414428

Article  PubMed  PubMed Central  Google Scholar 

Borghaei H et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosenberg JE et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/s0140-6736(16)00561-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Antonia SJ et al (2017) Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937

Article  PubMed  CAS  Google Scholar 

Kaufman HL et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374–1385. https://doi.org/10.1016/s1470-2045(16)30364-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Migden MR et al (2018) PD-1 blockade with Cemiplimab in Advanced Cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351. https://doi.org/10.1056/NEJMoa1805131

Article  PubMed  CAS  Google Scholar 

Oaknin A et al (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 10. https://doi.org/10.1136/jitc-2021-003777

Mai HQ et al (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 27:1536–1543. https://doi.org/10.1038/s41591-021-01444-0

Article  PubMed  CAS  Google Scholar 

Lu L et al (2022) Clinically approved combination immunotherapy: current status, limitations, and future perspective. Curr Res Immunol 3:118–127. https://doi.org/10.1016/j.crimmu.2022.05.003

Article  PubMed  PubMed Central  CAS  Google Scholar 

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events Associated with Immune Checkpoint Blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481

Article  PubMed  CAS  Google Scholar 

Gumusay O, Callan J, Rugo HS (2022) Immunotherapy toxicity: identification and management. Breast Cancer Res Treat 192:1–17. https://doi.org/10.1007/s10549-021-06480-5

Article  PubMed  PubMed Central  CAS  Google Scholar 

Johnson DB et al (2015) Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 51:2792–2799. https://doi.org/10.1016/j.ejca.2015.08.022

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marabelle A et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9

Article  PubMed  CAS  Google Scholar 

Vidotto T et al (2020) Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer 122:1732–1743. https://doi.org/10.1038/s41416-020-0834-6

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sade-Feldman M et al (2017) Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 8:1136. https://doi.org/10.1038/s41467-017-01062-w

Article  PubMed  PubMed Central  CAS  Google Scholar 

Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7:278. https://doi.org/10.1186/s40425-019-0768-9

Article  PubMed  PubMed Central  Google Scholar 

Twomey JD, Zhang B (2021) Cancer Immunotherapy Update: FDA-Approved checkpoint inhibitors and Companion Diagnostics. Aaps j 23:39. https://doi.org/10.1208/s12248-021-00574-0

Article  PubMed  Google Scholar 

Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561. https://doi.org/10.1038/363558a0

Article  PubMed  CAS  Google Scholar 

Marcus L, Lemery SJ, Keegan P, Pazdur RFDA (2019) Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753–3758. https://doi.org/10.1158/1078-0432.Ccr-18-4070

Article  PubMed  CAS  Google Scholar 

Taube JM et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074. https://doi.org/10.1158/1078-0432.Ccr-13-3271

Article  PubMed  PubMed Central  CAS  Google Scholar 

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287. https://doi.org/10.1038/nrc.2016.36

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burtness B et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928. https://doi.org/10.1016/s0140-6736(19)32591-7

Article  PubMed  CAS  Google Scholar 

Chan TA et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30:44–56. https://doi.org/10.1093/annonc/mdy495

Article  PubMed  CAS  Google Scholar 

Chalmers ZR et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https://doi.org/10.1186/s13073-017-0424-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hugo W et al (2016) Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44. https://doi.org/10.1016/j.cell.2016.02.065

Article